British Journal of Cancer · 2004 · 10 citations · 18 references
PharmacyOncologyPharmacologyCancer Drug Toxicity ManagementCancer PharmacologyOncology PharmacotherapyChemotherapy Dose CalculationChemotherapy Toxicity ManagementCombination ChemotherapyDose Adjustment In OncologyLung Cancer PharmacotherapyToxicity ManagementChemotherapy Dose-limiting ToxicityComplete Response AssessmentDose-limiting Toxicity AssessmentFebrile Neutropenia TreatmentFixed-dose DosingNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPartial Response Assessment
To determine the maximum-tolerated dose (MTD) and the recommended dose (RD) of paclitaxel administered weekly with a fixed dose of cisplatin, and to assess the toxicity and activity of this combination, we conducted a phase I/II trial in patients with advanced non-small-cell lung cancer (NSCLC). In this study, patients with stage IIIB/IV NSCLC were eligible. Paclitaxel, at a starting dose of 40 mg x m(-2) week(-1) on days 1, 8, and 15, was combined with a fixed dose of cisplatin 80 mg x m(-2) on day 1. Chemotherapy was given in a 4-week cycle. In this phase I/II study, 38 patients were enrolled. Dose-limiting toxicities (DLT) were neutropenia, fatigue, and omission of treatment due to leucopenia, thrombocytopenia, or febrile neutropenia. The MTD and RD were estimated to be 70 mg x m(-2). Of the 37 assessable patients, 23 had a partial response and one had a complete response. Overall response rate was 62.1% (95% confidence interval (CI): 46.5-77.7%). The progression-free survival, the median survival time, and the 1-year survival rate were 5.5 months, 13.7 months, and 56.9%, respectively. This regimen is tolerable and very active against advanced NSCLC, and its efficacy should be confirmed in a phase III study.
18
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002 · 3.7K citations
Medicine, Oncology, Pharmacology +11
Phyllis A. Wingo, T. Tong, S. Bolden · CA A Cancer Journal for Clinicians · 1995 · 1.4K citations · Full text
Medicine, Biostatistics, Oncology +17
Karen Kelly, John Crowley, Paul A. Bunn et al. · Journal of Clinical Oncology · 2001 · 1.1K citations
Medicine, Oncology, Pharmacology +17